Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | IGFBP3 | P17936 | 7/20 | 0.43 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.43 |
| ▸ | IGFBP5 | P24593 | 3/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.41 |
| ▸ | IGFBP1 | P08833 | 1/20 | 0.41 |
| ▸ | IGFBP2 | P18065 | 1/20 | 0.41 |
| ▸ | IGFBP4 | P22692 | 1/20 | 0.41 |
| ▸ | IGFBP6 | P24592 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.38 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908985 | 0.88 | ALOX15 (0.48) | IGFBP3IP6K1IGFBP5IGFBP1IGFBP2 | |
| SCHEMBL2903071 | 0.84 | IGFBP3 (0.44) | IGFBP3IGFBP5IGFBP1IGFBP2IGFBP4 | |
| SCHEMBL2909497 | 0.84 | GAA (0.43) | LCKIP6K1ALOX15DPP4 | |
| SCHEMBL2907367 | 0.80 | IGFBP3 (0.48) | IGFBP3IGFBP5ALOX15TSHRHIF1A | |
| SCHEMBL975885 | 0.80 | IGFBP5 (0.43) | IGFBP3IGFBP5ALOX15TSHRHIF1A | |
| SCHEMBL11827386 | 0.79 | IGFBP5 (0.47) | IGFBP3IGFBP5IGFBP1IGFBP2IGFBP4 | |
| SCHEMBL11823904 | 0.77 | IGFBP5 (0.46) | IGFBP3IGFBP5IGFBP1IGFBP2IGFBP4 | |
| SCHEMBL9039085 | 0.77 | ALDH1A1 (0.48) | ALOX15 | |
| SCHEMBL1305232 | 0.77 | ALDH1A1 (0.49) | IGFBP3IGFBP5HIF1A | |
| SCHEMBL4471851 | 0.77 | IGFBP5 (0.41) | IGFBP3IGFBP5ALOX15TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578423-B1 | 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | BAYER SCHERING PHARMA AG (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-7176207-B2 | Anticoagulants; antithrombotic agents in the treatment and prevention of thrombosis | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-02-13 | — | — | US | disclosed |
| US-7084142-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-08-01 | — | — | US | disclosed |
| US-20060135532-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-22 | — | — | US | disclosed |
| US-20060122188-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-08 | — | — | US | disclosed |
| US-7056923-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-06 | — | — | US | disclosed |
| US-7026323-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-11 | — | — | US | disclosed |
| CN-1747732-A | 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists | SCHERING AG (DE) | 2006-03-15 | — | — | CN | disclosed |
| US-6995156-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-02-07 | — | — | US | disclosed |
| EP-1578423-A1 | 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-20050065163-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | disclosed |
| US-6861424-B2 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20050038037-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-02-17 | — | — | US | disclosed |
| US-20040138229-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | US | disclosed |
| WO-2004052366-A1 | 2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | WO | disclosed |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122188-A1 | Platelet adenosine diphosphate receptor antagonists | TBXA2R, P2RY1, ADORA1 | LCK 4567/4885IGFBP3 4170/4885IP6K1 637/4885 |
| US-20050065163-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA2B, ADORA1, TBXA2R | LCK 4675/4885IGFBP3 3464/4885IP6K1 515/4885 |
| US-20050038037-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA2B, ADORA1, TBXA2R | LCK 4675/4885IGFBP3 3464/4885IP6K1 515/4885 |
| US-20040138229-A1 | Platelet adenosine diphosphate receptor antagonists | TBXA2R, ADORA1, P2RY1 | LCK 4575/4885IGFBP3 3914/4885IP6K1 387/4885 |
| US-20030060474-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA1, TBXA2R, ADORA2B | LCK 4696/4885IGFBP3 3531/4885IP6K1 282/4885 |
| US-20060135532-A1 | Platelet adenosine diphosphate receptor antagonists | ADORA1, ADORA2B, TBXA2R | LCK 4659/4885IGFBP3 3490/4885IP6K1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.